E-viri
PDF
Recenzirano
Odprti dostop
-
Darras, Basil T; Masson, Riccardo; Mazurkiewicz-Bełdzińska, Maria; Rose, Kristy; Xiong, Hui; Zanoteli, Edmar; Baranello, Giovanni; Bruno, Claudio; Vlodavets, Dmitry; Wang, Yi; El-Khairi, Muna; Gerber, Marianne; Gorni, Ksenija; Khwaja, Omar; Kletzl, Heidemarie; Scalco, Renata S; Fontoura, Paulo; Servais, Laurent
The New England journal of medicine, 07/2021, Letnik: 385, Številka: 5Journal Article, Web Resource
The pre-mRNA SMN2 splicing modifier risdiplam was administered orally to 41 infants with type 1 spinal muscular atrophy. After 12 months of treatment, 12 infants were able to sit without support, and most had better scores on motor-performance scales than the upper limit of confidence intervals from historical controls.
